MosesAC, KoenenC. Response to Swinnen et al. Diabetes Technol Ther, 2010; 12:503–505.
2.
SwinnenSG, SnoekFJ, DainMP, DeVriesJH, HoekstraJB, HollemanF. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther, 2009; 11:739–743.
3.
SwinnenSG, DainMP, AronsonR, DaviesM, GersteinHC, PfeifferAF, SnoekFJ, DeVriesJH, HoekstraJB, HollemanF. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care, 2010; 33:1176–1178.
4.
European Medicines Agency: Levemir. European Public Assessment Report Scientific Discussion, 2004. www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/093604en6.pdf. 2010 June 16.
5.
HermansenK, DaviesM, DerezinskiT, MartinezRG, ClausonP, HomeP. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 2006; 29:1269–1274.
6.
RosenstockJ, DaviesM, HomePD, LarsenJ, KoenenC, SchernthanerG. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 2008; 51:408–416.
7.
KoenenC. How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus?Nat Clin Pract Endocrinol Metab, 2008; 4,10:E1.
8.
HolmanRR, ThorneKI, FarmerAJ, DaviesMJ, KeenanJF, PaulS, LevyJC. 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med, 2007; 357:1716–1730.
9.
Philis-TsimikasA, CharpentierG, ClausonP, RavnGM, RobertsVL, ThorsteinssonB. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther, 2006; 28:1569–1581.
10.
Novo Nordisk. Levemir US Prescribing information. www.levemir-us.com/downloads/levemir-prescribing-information.pdf. 2010 June 16.
11.
European Medicines Agency: Levemir. Summary of Product Characteristics. www.ema.europa.eu/humandocs/PDFs/EPAR/levemir/emea-combined-h528en.pdf. 2010 June 16.
12.
DeVriesJH, NattrassM, PieberTR. Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes Metab Res Rev, 2007; 23:441–454.
13.
RiddleMC, RosenstockJ, GerichJ. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003; 26:3080–3086.
